Peter Grayson

Vasculitis doctor and researcher, father of three girls, diehard Celtics fan, musician

[Peter Grayson @petercgrayson]

I’m out of here. Will find different platforms to share research results. ✌️

[Peter Grayson @petercgrayson]

@SgRheumer @ACRheum I think your pic from the Takayasu’s session was a little early! The session was completely full for the talks - which is a big deal for a rare disease that certainly needs more attention!

[Peter Grayson @petercgrayson]

@Amansharmapgi @TerrierBen @philseo @dpgi_chandigarh @IJRheum @IndianRheum @DurgaPrasannaM1 @dada2foundation @maferradastrong @shimonakTOI What a legend! Great to see you!

[Peter Grayson @petercgrayson]

@EBRheum @RheumNow Didn’t they allow patients with a prior history of TCZ to be included but specifically excluded those patients who were previously treatment refractory to TCZ?

[Peter Grayson @petercgrayson]

@emmamgroarke @NIH I love that #149

[Peter Grayson @petercgrayson]

@drdavidliew @VasculitisUMCG @RheumNow Lots of data converging to this observation. Only scary if it impacts longterm outcomes. Treat to target with imaging based outcomes has not proven to be wise across a spectrum of rheum diseases. Maybe future drugs will eliminate vascular inflammation. Maybe won’t matter.

[NIAMS @NIH_NIAMS]

News: Skin manifestations in VEXAS syndrome are common and provide an important early clue to the diagnosis of this life-threatening disease.

Read the full NIAMS-led study via @JAMADerm 🔒. Abstract: https://t.co/2DVCbJosX2

[Sophie Georgin-Lavialle @SophieGeorgin]

A look back at the first workshop on #VEXAS syndrome! > 100 participants from 19 countries came in Paris. Thanks to the support of @contactfai2r. @TerrierBen @mekinian2 @petercgrayson @maferradastrong @KosmiderO @_ERNRITA @RimBourguiba1 @CiprianJurcut

[Peter Grayson @petercgrayson]

Many thanks to our French colleagues for hosting the first international VEXAS Congress in Paris. The only thing that was better than the science was the friendship. We had the best time with you! @SophieGeorgin @TerrierBen @mekinian2 @bhavishap29 @emmamgroarke @maferradastrong

[Peter Grayson @petercgrayson]

@tcboyle A haiku in every bottle

[Peter Grayson @petercgrayson]

@GrantSchulert Two kinds of grown ups: those who hate Disney and those who love it. Choose love!

[Alex Bick @AlexBickMDPhD]

UBA1 somatic mutations of indeterminate potential? our provocative finding in @AllofUsResearch led by @rheumrob with @jamesfbrogan, @kwbyram & @petercgrayson
@VUMC_MedPSTP, @VUMCRheum @NIH_NIAMS

[Peter Grayson @petercgrayson]

Population databases have shown very different findings related to VEXAS, reflecting selection bias. In AllofUs, 74 people with VEXAS mutations, 62 of them were female, 100% were p.Met41Leu, unclear if they have any disease phenotype. Terrific work led by @rheumrob !!!

[ACR_Journals @ACR_Journals]

Somatic mutations in UBA1 cause VEXAS, a severe inflammatory syndrome. For the first time, researchers have found 74 people with the mutation who don't have VEXAS. Studying them may give a peek into the earliest phases of disease.

In A&R
https://t.co/vrknbiYBMK
@rheumrob

[Peter Grayson @petercgrayson]

@MCMarquesMD @DrPowerHays Tasha Morrison calls me Steve so I am pretty much good with whatever you want to do! As long as it’s not Dr Grayson!

[Peter Grayson @petercgrayson]

@BharatKumarMD @LauraLewMad11 @EcemSevimMD @ACRheum We’ve been discussing this quite a bit lately. We just need a solid name 🤔

[Peter Grayson @petercgrayson]

Looks like CH is more a marker of inflammaging that primary driver of vasculitis - but may modify disease course

[Peter Grayson @petercgrayson]

Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu’s arteritis, ANCA-associated vasculitis and giant cell arteritis https://t.co/WfsL2Tlsnv

New collaborative work from rheum and heme at NIH @fergutierrezro1 @bhavishap29 @KQuinnRheum @NealSYoung1

[Peter Grayson @petercgrayson]

We looked at CH prevalence in three forms of vasculitis that span the age spectrum.

Found that:
1. Age stronger driver of CH than vasculitis
2. Mostly small clones in DNMT3A and TET2
3. Association of clone size and relapse in GCA (unclear direction of association)